Patents by Inventor Hans-Ulrich Demuth

Hans-Ulrich Demuth has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210198189
    Abstract: The present invention relates to novel hydroxamic acid derivatives as inhibitors of meprin ? and/or ?, pharmaceutical compositions comprising such compounds, methods for treatment or prophylaxis of diseases or conditions, especially such that are related to meprin ? and/or ?, and compounds and pharmaceutical compositions for use in such methods.
    Type: Application
    Filed: March 8, 2021
    Publication date: July 1, 2021
    Applicant: Vivoryon Therapeutics AG
    Inventors: Michael Wermann, Mirko Buchholz, Hans-Ulrich Demuth, Daniel Ramsbeck, Dagmar Schlenzig, Stephen Schilling
  • Patent number: 10975019
    Abstract: The present invention relates to novel hydroxamic acid derivatives as inhibitors of meprin ? and/or ?, pharmaceutical compositions comprising such compounds, methods for treatment or prophylaxis of diseases or conditions, especially such that are related to meprin ? and/or ?, and compounds and pharmaceutical compositions for use in such methods.
    Type: Grant
    Filed: April 18, 2017
    Date of Patent: April 13, 2021
    Assignee: Vivoryon Therapeutics AG
    Inventors: Michael Wermann, Mirko Buchholz, Hans-Ulrich Demuth, Daniel Ramsbeck, Dagmar Schlenzig, Stephen Schilling
  • Publication number: 20200264197
    Abstract: The present invention can be included in the field of medicine. Specifically, the present invention provides antibodies and antigen-binding fragments thereof which can bind isoAsp7 amyloid ? (A?) and a pharmaceutical composition comprising the antibodies or antigen-binding fragments thereof. IsoAsp7 A? can be found in plaques of Alzheimer's patients and is thus a suitable target for the treatment and/or prevention of A?-related diseases such as Alzheimer's disease. Thus, the antibodies, antigen-binding fragments thereof and the pharmaceutical composition comprising either can be used to treat and/or prevent neurodegenerative diseases. Further, the present invention provides hybridoma cell lines, the use of the antibodies or antigen-binding fragments thereof for the diagnosis and/or prognosis of a neurodegenerative disease and a method for detecting isoAsp7 A? in an isolated sample.
    Type: Application
    Filed: July 17, 2018
    Publication date: August 20, 2020
    Inventors: Anke PIECHOTTA, Kathrin GNOTH, Holger CYNIS, Jens-Ulrich RAHFELD, Stephan SCHILLING, Hans-Ulrich DEMUTH
  • Publication number: 20190367511
    Abstract: The present invention relates to bacterial glutaminyl cyclases and inhibitors thereof for use in the treatment of periodontitis and related conditions, and provides a bacterial glutaminyl cyclase (bacQC); an antibody which recognizes the bacQC, a method for identifying an inhibitor of the bacQC; a compound according to Formula (I); a pharmaceutical composition comprising a bacQC inhibitor compound; a bacQC inhibitor compound and/or a pharmaceutical composition for use in a method for treatment of the human or animal body, for use in a method for therapy or prophylaxis of a bacterial infection, and for use in a method for therapy and/or prophylaxis of an acute, chronic or recurrent periodontal disease.
    Type: Application
    Filed: December 1, 2017
    Publication date: December 5, 2019
    Inventors: Jan Potempa, Sigrun Eick, Nadine Taudte, Jens-Ulrich Rahfeld, Mirko Buchholz, Hans-Ulrich Demuth
  • Publication number: 20190127317
    Abstract: The present invention relates to novel hydroxamic acid derivatives as inhibitors of meprin ? and/or ?, pharmaceutical compositions comprising such compounds, methods for treatment or prophylaxis of diseases or conditions, especially such that are related to meprin ? and/or ?, and compounds and pharmaceutical compositions for use in such methods.
    Type: Application
    Filed: April 18, 2017
    Publication date: May 2, 2019
    Inventors: Michael Wermann, Mirko Buchholz, Hans-Ulrich Demuth, Daniel Ramsbeck, Dagmar Schlenzig, Stephen Schilling
  • Publication number: 20180228825
    Abstract: The invention relates to the use of a compound of formula (I), or a composition containing the compound, as glutaminyl cyclase (QC) inhibitor and to methods of preparation.
    Type: Application
    Filed: September 15, 2016
    Publication date: August 16, 2018
    Applicants: Hochschule Anhalt, Leibniz-Institut Für Pflanzenbiochemie (IPB)
    Inventors: Stephanie Hielscher-Michael, Carola Griehl, Hans-Ulrich Demuth, Stephan Schilling, Ludger Wessjohann, Norbert Arnold
  • Patent number: 9676843
    Abstract: Diagnostic assays for the diagnosis of amyloidosis, in particular Alzheimer's disease, and related aspects. In particular, monoclonal antibodies and an antibody assay are provided.
    Type: Grant
    Filed: September 3, 2015
    Date of Patent: June 13, 2017
    Assignee: PROBIODRUG AG
    Inventors: Hans-Ulrich Demuth, Stephan Schilling, Martin Kleinschmidt, Kathrin Gnoth, Anita Reisenauer-Schaupp, Jens-Ulrich Rahfeld, Sonja Kampfer
  • Patent number: 9657089
    Abstract: Diagnostic assays for the diagnosis of amyloidosis, in particular Alzheimer's disease, and related aspects. In particular, monoclonal antibodies and an antibody assay are provided.
    Type: Grant
    Filed: May 19, 2014
    Date of Patent: May 23, 2017
    Assignee: PROBIODRUG AG
    Inventors: Martin Kleinschmidt, Stephan Schilling, Jens-Ulrich Rahfeld, Kristin Ebermann, Hans-Ulrich Demuth
  • Patent number: 9650362
    Abstract: The invention relates to novel pyrrolidine derivatives of formula (I): wherein R1, R2 and R3 are as defined herein, as inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5). QC catalyzes the intramolecular cyclization of N-terminal glutamine residues into pyroglutamic acid (5-oxo-prolyl, pGlu*) under liberation of ammonia and the intramolecular cyclization of N-terminal glutamate residues into pyroglutamic acid under liberation of water.
    Type: Grant
    Filed: September 23, 2015
    Date of Patent: May 16, 2017
    Assignee: PROBIODRUG AG
    Inventors: Ulrich Heiser, Daniel Ramsbeck, Robert Sommer, Antje Meyer, Torsten Hoffmann, Livia Boehme, Hans-Ulrich Demuth
  • Publication number: 20170097365
    Abstract: A method for predicting, diagnosing and prognosticating a neurodegenerative disease, such as Alzheimer's disease (AD), Mild Cognitive Impairment (MCI) and neurodegeneration in Down's syndrome (NDS) using glutaminyl cyclase (QC) as a diagnostic/prognostic indicator. The use of antibodies binding to QC and kits for performing said diagnostic method are also provided.
    Type: Application
    Filed: December 14, 2016
    Publication date: April 6, 2017
    Inventors: Hans-Ulrich Demuth, Stephan Schilling, Martin Kleinschmidt, Jens-Ulrich Rahfeld, Astrid Kehlen, Monique Haegele
  • Patent number: 9611296
    Abstract: Peptides that bind to amino-terminal truncated pEA?3-42, the free glutamic acid residue of which lies in position 3 or 11 in the form of cyclized pyroglutamate. Four oligopeptides were identified using mirror image phage display technology.
    Type: Grant
    Filed: September 25, 2013
    Date of Patent: April 4, 2017
    Assignee: Forschungszentrum Juelich GmbH
    Inventors: Dieter Willbold, Susanne Aileen Funke, Yeliz Cinar, Dirk Bartnik, Hans-Ulrich Demuth, Martin Kleinschmidt, Hans-Henning Ludwig
  • Patent number: 9610368
    Abstract: Radiolabeled glutaminylcyclase (QC) inhibitors as imaging agents, in particular, but not exclusively, as medical imaging agents for the detection of neurological disorders; and pharmaceutical compositions, methods and kits for detecting neurological disorders, using the radiolabeled inhibitors.
    Type: Grant
    Filed: December 15, 2014
    Date of Patent: April 4, 2017
    Assignee: PROBIODRUG AG
    Inventors: Ulrich Heiser, Daniel Ramsbeck, Hans-Ulrich Demuth
  • Publication number: 20170007582
    Abstract: The present invention comprises the use of activity-reducing effectors of dipeptidyl peptidase (DP IV) and DP IV-analogous enzyme activity in the blood of a mammal to lower elevated post-prandial and basal blood glucose levels in mammalian organisms. The invention further comprises the use of activity-reducing effectors of dipeptidyl peptidase (DP IV) and DP IV-analogous enzyme activity in the blood of a mammal to increase the half-life of incretins in vivo.
    Type: Application
    Filed: February 12, 2016
    Publication date: January 12, 2017
    Inventors: Hans-Ulrich Demuth, Fred Rosche, Joem Schmidt, Robert P. Pauly, Christopher H.S. McIntosh, Ray A. Pederson
  • Patent number: 9512115
    Abstract: The invention relates to a compound of formula (I) or a pharmaceutically acceptable salt, solvate or polymorph thereof, including all tautomers and stereoisomers thereof, wherein R1, R2, R3, R4 and R5 are as defined herein, as inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5). QC catalyzes the intramolecular cyclization of N-terminal glutamine residues into pyroglutamic acid (5-oxo-prolyl, pGlu*) under liberation of ammonia and the intramolecular cyclization of N-terminal glutamate residues into pyroglutamic acid under liberation of water.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: December 6, 2016
    Assignee: PROBIODRUG AG
    Inventors: Ulrich Heiser, Mirko Buchholz, Robert Sommer, Antje Meyer, Hans-Ulrich Demuth
  • Patent number: 9462793
    Abstract: The present invention provides a knock-out non-human animal, in particular a mouse carrying a Qpct knock-out mutation. The present invention additionally provides the respective cells and cell lines and methods and compositions for evaluating agents that affect Qpct, for use in compositions for the treatment of Qpct-related diseases.
    Type: Grant
    Filed: January 14, 2009
    Date of Patent: October 11, 2016
    Assignee: PROBIODRUG AG
    Inventors: Stephan Schilling, Torsten Hoffmann, Hans-Ulrich Demuth
  • Patent number: 9277737
    Abstract: A knock-out non-human animal, in particular a mouse, carrying a QPCTL knock-out mutation. Additionally, respective cells and cell lines and methods and compositions for evaluating agents that affect QPCTL, for use in compositions for the treatment of QPCTL-related diseases are disclosed.
    Type: Grant
    Filed: May 6, 2013
    Date of Patent: March 8, 2016
    Assignee: PROBIODRUG AG
    Inventors: Hans-Ulrich Demuth, Anett Stephan, Birgit Koch, Holger Cynis, Stephan Schilling, Reinhard Sedlmeier, Sigrid Graubner
  • Publication number: 20160053001
    Abstract: Novel diagnostic assays for the diagnosis of amyloidosis, in particular Alzheimer's disease, and related aspects. In particular, monoclonal antibodies and an antibody assay are provided.
    Type: Application
    Filed: September 3, 2015
    Publication date: February 25, 2016
    Inventors: Hans-Ulrich Demuth, Stephan Schilling, Martin Kleinschmidt, Kathrin Gans, Anita Reisenauer-Schaupp, Jens-Ulrich Rahfeld, Sonja Kampfer
  • Publication number: 20160039795
    Abstract: The invention relates to novel pyrrolidine derivatives of formula (I): wherein R1, R2 and R3 are as defined herein, as inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5). QC catalyzes the intramolecular cyclization of N-terminal glutamine residues into pyroglutamic acid (5-oxo-prolyl, pGlu*) under liberation of ammonia and the intramolecular cyclization of N-terminal glutamate residues into pyroglutamic acid under liberation of water.
    Type: Application
    Filed: September 23, 2015
    Publication date: February 11, 2016
    Inventors: Ulrich Heiser, Daniel Ramsbeck, Robert Sommer, Antje Meyer, Torsten Hoffmann, Livia Boehme, Hans-Ulrich Demuth
  • Publication number: 20160031869
    Abstract: The invention relates to a compound of formula (I) or a pharmaceutically acceptable salt, solvate or polymorph thereof, including all tautomers and stereoisomers thereof, wherein R1, R2, R3, R4 and R5 are as defined herein, as inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5). QC catalyzes the intramolecular cyclization of N-terminal glutamine residues into pyroglutamic acid (5-oxo-prolyl, pGlu*) under liberation of ammonia and the intramolecular cyclization of N-terminal glutamate residues into pyroglutamic acid under liberation of water.
    Type: Application
    Filed: March 14, 2014
    Publication date: February 4, 2016
    Inventors: Ulrich Heiser, Mirko Buchholz, Robert Sommer, Antje Meyer, Hans-Ulrich Demuth
  • Publication number: 20150361167
    Abstract: Monoclonal antibodies which bind specifically to the proinflammatory cytokine pyroglutamate MCP-1 (MCP-1 N1pE).
    Type: Application
    Filed: August 31, 2015
    Publication date: December 17, 2015
    Inventors: Holger Cynis, Hans-Ulrich Demuth, Jens-Ulrich Rahfeld, Stephan Schilling, Kathrin Gans, Sonja Kampfer